By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Recordati S.p.A 

Via M. Civitali, 1

Milan    20148  Italy
Phone: 39-02-487871 Fax: 39-02-40073747




Forest  Licensing agreement for the development of lercanidipine, a long-acting dihydropyridine calcium channel blocker for the treatment of hypertension.

Digital Gene Technologies  Atherosclerosis

Company News
AstraZeneca PLC (AZN) Offloads Heart Drugs to Recordati in $300 Million Deal to Pump Up R&D 5/22/2017 5:41:11 AM
Recordati Acquires Canadian Rights To CYSTADANE (Betaine Anhydrous For Oral Solution) 4/20/2017 8:44:54 AM
Recordati Establishes Canadian Presence With Launch Of Recordati Rare Diseases Canada Inc. 4/13/2017 11:37:43 AM
Recordati: Board Approves The 2016 Accounts. Sales € 1,153.9 Million (+10.1%), Operating Income € 327.4 Million (+17.6%) And Net Income € 237.4 Million (+19.4%). 2016 Dividend € 0.70 (+16.7%) 3/1/2017 11:29:52 AM
Recordati Signs An Exclusive License Agreement With The Meyer Hospital In Florence 2/27/2017 8:18:33 AM
Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability. New Three Year Business Plan Presented 2/9/2017 8:21:28 AM
Recordati To Meet With The Financial Community And Specialized Press In Milan 2/1/2017 7:41:46 AM
Recordati Announces Marketing Approval For Cystadrops 1/27/2017 7:53:51 AM
Apricus Biosciences (APRI) Announces The Launch Of Vitaros In The Czech Republic And Slovakia By Recordati 9/21/2016 9:19:03 AM
Apricus Biosciences (APRI) Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati 9/6/2016 8:07:03 AM